Security key
45175G207
ImageneBio, Inc. - Common Stock, $0.001 par value (IMA)
CUSIP: 45175G207
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, $0.001 par value
- Total 13F shares
- 4,705,090
- Total 13F value
- $38,346,527
- Share change
- +4,705,066
- SEC-reported price per share
- $8.15
- Number of holders
- 32
- Value change
- +$38,346,331
- Number of buys
- 31
- Shares outstanding
- 11,212,141
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
32
Top holders
10
IMA full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
ImageneBio, Inc. SEC filings
ImageneBio, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 45175G207
Recent filing periods:
Ownership snapshot
Top reported holders of IMA - ImageneBio, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BIOTECHNOLOGY VALUE FUND L P
Disclosed value leader
Atlas Venture Life Scienc...
Comparable rows
15/15
Latest evidence
25 Jul 2025
13D/G
13F
3/4/5
Lead comparable stake: 8.3%
13D/G row: BIOTECHNOLOGY VALUE FUND L P
Showing 1-6 of 15 holder rows.
Quick read
BIOTECHNOLOGY VALUE FUND L P leads the comparable SEC ownership view at 8.3%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BIOTECHNOLOGY VALUE FUND L P's linked filing trail.
Comparable ownership
Top 5
BIOTECHNOLOGY VALUE FUND L P
8.3%
ORBIMED ADVISORS LLC
6.9%
GILEAD SCIENCES, INC.
3.6%
Atlas Venture Fund X, L.P.
2.1%
BML Investment Partners, L.P.
1.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
8.3%
|
$4,246,958
4,006,564 shares
|
$0 | 31 Dec 2024 |
| ORBIMED ADVISORS LLC |
13F
13D/G
Company
|
6.9%
from 13D/G
|
$4,742,740
3,539,358 shares
|
— | 30 Jun 2025 |
| GILEAD SCIENCES, INC. |
13D/G
13F
Company
|
3.6%
|
$1,612,591
1,521,312 shares
|
$0 | 31 Dec 2024 |
| Atlas Venture Fund X, L.P. |
13D/G
|
2.1%
|
—
241,800 shares
|
$0 | 25 Jul 2025 |
| BML Investment Partners, L.P. |
13D/G
Leonard Braden Michael
|
1.9%
|
—
220,832 shares
|
$0 | 25 Jul 2025 |
| Jotin Marango |
3/4/5
Chief Financial Officer
|
0.1%
|
$191,265
11,146 shares
|
— | 25 Jul 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
32
Shares
4,705,090
Rows available
32
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q4 2025 Across Filers
Q4 2025 holders
40
Q3 2025 holders
32
Holder diff
-8
| Investor | Q4 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q4 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend